uniQure QURE reported initial six-month follow-up results from the first low-dose cohort of six patients enrolled in its ongoing phase I/IIa study evaluating AMT-260, an investigational gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results